195 related articles for article (PubMed ID: 29158855)
1. Clinical Evaluation of Terap C Vaccine in Combined Treatment with Interferon and Ribavirin in Patients with Hepatitis C.
Zaily DG; Marlen CF; Santiago DC; Gillian MD; Carmen VS; Zurina CE; Enrique R AS; Liz AL; Lisset GF; Sacha LDV; Elena FB
Curr Ther Res Clin Exp; 2017; 85():20-28. PubMed ID: 29158855
[TBL] [Abstract][Full Text] [Related]
2. Interferon beta 1a versus interferon beta 1a plus ribavirin for the treatment of chronic hepatitis C in Chinese patients: a randomized, placebo-controlled trial.
Han Q; Liu Z; Kang W; Li H; Zhang L; Zhang N
Dig Dis Sci; 2008 Aug; 53(8):2238-45. PubMed ID: 18080763
[TBL] [Abstract][Full Text] [Related]
3. Low Efficacy of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4 and HIV Coinfection.
Macías J; López-Cortés LF; Téllez F; Recio E; Ojeda-Burgos G; Ríos MJ; Rivero-Juárez A; Delgado M; Rivas-Jeremías ; Pineda JA
PLoS One; 2015; 10(12):e0143492. PubMed ID: 26640956
[TBL] [Abstract][Full Text] [Related]
4. Retreatment of hepatitis C patients with pegylated interferon combined with ribavirin in non-responders to interferon plus ribavirin. Is it different in real life?
Gonçales FL; Moma CA; Vigani AG; Angerami AF; Gonçales ES; Tozzo R; Pavan MH; Gonçales NS
BMC Infect Dis; 2010 Jul; 10():212. PubMed ID: 20646277
[TBL] [Abstract][Full Text] [Related]
5. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.
Manns M; Marcellin P; Poordad F; de Araujo ES; Buti M; Horsmans Y; Janczewska E; Villamil F; Scott J; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Sinha R; Beumont-Mauviel M
Lancet; 2014 Aug; 384(9941):414-26. PubMed ID: 24907224
[TBL] [Abstract][Full Text] [Related]
6. Sequence heterogeneity in NS5A of hepatitis C virus genotypes 2a and 2b and clinical outcome of pegylated-interferon/ribavirin therapy.
El-Shamy A; Shoji I; Kim SR; Ide Y; Imoto S; Deng L; Yoon S; Fujisawa T; Tani S; Yano Y; Seo Y; Azuma T; Hotta H
PLoS One; 2012; 7(2):e30513. PubMed ID: 22319571
[TBL] [Abstract][Full Text] [Related]
7. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.
Shepherd J; Brodin H; Cave C; Waugh N; Price A; Gabbay J
Health Technol Assess; 2004 Oct; 8(39):iii-iv, 1-125. PubMed ID: 15461877
[TBL] [Abstract][Full Text] [Related]
8. Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1.
Manns MP; Markova AA; Calle Serrano B; Cornberg M
Liver Int; 2012 Feb; 32 Suppl 1():27-31. PubMed ID: 22212568
[TBL] [Abstract][Full Text] [Related]
9. Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonresponders.
Rustgi VK; Lee WM; Lawitz E; Gordon SC; Afdhal N; Poordad F; Bonkovsky HL; Bengtsson L; Chandorkar G; Harding M; McNair L; Aalyson M; Alam J; Kauffman R; Gharakhanian S; McHutchison JG;
Hepatology; 2009 Dec; 50(6):1719-26. PubMed ID: 19852040
[TBL] [Abstract][Full Text] [Related]
10. Hematological Adverse events and Sustained Viral Response in Children Undergoing Therapy for Chronic Hepatitis C Infection.
Pawlowska M; Pilarczyk M; Foksinska A; Smukalska E; Halota W
Hepat Mon; 2011 Dec; 11(12):968-74. PubMed ID: 22368680
[TBL] [Abstract][Full Text] [Related]
11. Simeprevir (TMC435) once daily with peginterferon-α-2b and ribavirin in patients with genotype 1 hepatitis C virus infection: The CONCERTO-4 study.
Kumada H; Hayashi N; Izumi N; Okanoue T; Tsubouchi H; Yatsuhashi H; Kato M; Rito K; Komada Y; Seto C; Goto S
Hepatol Res; 2015 May; 45(5):501-13. PubMed ID: 24961662
[TBL] [Abstract][Full Text] [Related]
12. Telaprevir for HIV/hepatitis C virus-coinfected patients failing treatment with pegylated interferon/ribavirin (ANRS HC26 TelapreVIH): an open-label, single-arm, phase 2 trial.
Cotte L; Braun J; Lascoux-Combe C; Vincent C; Valantin MA; Sogni P; Lacombe K; Neau D; Aumaitre H; Batisse D; de Truchis P; Gervais A; Michelet C; Morlat P; Vittecoq D; Rosa I; Bertucci I; Chevaliez S; Aboulker JP; Molina JM;
Clin Infect Dis; 2014 Dec; 59(12):1768-76. PubMed ID: 25139963
[TBL] [Abstract][Full Text] [Related]
13. Clinical experience with nonstandard doses ofinterferon alfa-2b and ribavirin in the treatment of chronic hepatitis C infection: A retrospective analysis.
Hare CB; Loveland JJ; Chu A; Morris JA; Gotz V; Klaskala W
Curr Ther Res Clin Exp; 2005 Sep; 66(5):433-50. PubMed ID: 24790244
[TBL] [Abstract][Full Text] [Related]
14. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients.
Laguno M; Murillas J; Blanco JL; Martínez E; Miquel R; Sánchez-Tapias JM; Bargallo X; García-Criado A; de Lazzari E; Larrousse M; León A; Loncá M; Milinkovic A; Gatell JM; Mallolas J
AIDS; 2004 Sep; 18(13):F27-36. PubMed ID: 15316335
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy and safety of pegylated interferon α-2b injection (Y shape, 40 kD) in treatment of patients with genotype 1/6 chronic hepatitis C].
Feng B; Shang J; Wu SH; Chen H; Han Y; Li YQ; Zhang DZ; Zhao LF; Wei SF; Mao Q; Yin CB; Han T; Wang MR; Chen SJ; Li J; Xie Q; Zhen Z; Gao ZL; Zhang YX; Gong GZ; Yang DL; Pan C; Sheng JF; Tang H; Ning Q; Shi GF; Niu JQ; Luo GH; Sun YT; You H; Wang GQ; Zhang LL; Peng J; Zhang Q; Liu JJ; Chen CW; Chen XY; Zhao W; Wang RH; Sun L; Wei L
Zhonghua Gan Zang Bing Za Zhi; 2017 Mar; 25(3):187-194. PubMed ID: 28482405
[No Abstract] [Full Text] [Related]
16. Daily versus thrice-weekly interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected persons: a multicenter randomized controlled trial.
Sulkowski MS; Felizarta F; Smith C; Slim J; Berggren R; Goodman R; Ball L; Khalili M; Dieterich DT;
J Acquir Immune Defic Syndr; 2004 Apr; 35(5):464-72. PubMed ID: 15021311
[TBL] [Abstract][Full Text] [Related]
17. Interferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation.
Shepherd J; Jones J; Hartwell D; Davidson P; Price A; Waugh N
Health Technol Assess; 2007 Mar; 11(11):1-205, iii. PubMed ID: 17346498
[TBL] [Abstract][Full Text] [Related]
18. Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients.
Laguno M; Cifuentes C; Murillas J; Veloso S; Larrousse M; Payeras A; Bonet L; Vidal F; Milinkovic A; Bassa A; Villalonga C; Pérez I; Tural C; Martínez-Rebollar M; Calvo M; Blanco JL; Martínez E; Sánchez-Tapias JM; Gatell JM; Mallolas J
Hepatology; 2009 Jan; 49(1):22-31. PubMed ID: 19085908
[TBL] [Abstract][Full Text] [Related]
19. Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV-HCV co-infected patients: final results of the Spanish BOC HIV-HCV Study.
Laguno M; Von Wichmann MA; Van den Eynde E; Navarro J; Cifuentes C; Murillas J; Veloso S; Martínez-Rebollar M; Guardiola JM; Jou A; Gómez-Sirvent JL; Cervantes M; Pineda JA; López-Calvo S; Carrero A; Montes ML; Deig E; Tapiz A; Ruiz-Mesa JD; Cruceta A; de Lazzari E; Mallolas J
Int J Infect Dis; 2016 Dec; 53():46-51. PubMed ID: 27815225
[TBL] [Abstract][Full Text] [Related]
20. Randomized trial of high-dose interferon-alpha-2b combined with ribavirin in patients with chronic hepatitis C: Correlation between amino acid substitutions in the core/NS5A region and virological response to interferon therapy.
Mori N; Imamura M; Kawakami Y; Saneto H; Kawaoka T; Takaki S; Aikata H; Takahashi S; Chayama K;
J Med Virol; 2009 Apr; 81(4):640-9. PubMed ID: 19235866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
